Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Effects of CM93 in Subjects With Recurrent Glioblastoma (rGBM) Characterized by Epidermal Growth Factor Receptor (EGFR) Mutation or Amplification

NCT04933422 is registered in ClinicalTrials.gov with Crimson Biopharm Inc. as lead sponsor.

NCT NCT04933422
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04933422 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Effects of CM93 in Subjects With Recurrent Glioblastoma (rGBM) Characterized by Epidermal Growth Factor Receptor (EGFR) Mutation or Amplification
Lead sponsor
Crimson Biopharm Inc.
Phase
Phase 1
Overall status
Not yet recruiting
Start date
January 31, 2027
Completion date
July 31, 2029
Enrollment
72 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma